Business Context and Reporting Period
This Form 8-K was filed by Neuphoria Therapeutics Inc. on January 10, 2025. The Company, an emerging growth company incorporated in Delaware, reported a significant corporate governance event regarding its listing status on The Nasdaq Stock Market LLC under the trading symbol NEUP.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance regarding stock listing requirements.
Material Changes
The primary material event is the resolution of a prior listing deficiency:
- Regained Compliance: The Company received confirmation from Nasdaq that it has regained compliance with Listing Rule 5450(a)(1) (Minimum Bid Price Requirement).
- Compliance Period: The Company maintained a minimum closing bid price of $1.00 or greater per share for 10 consecutive business days from December 24, 2024, through January 8, 2025.
- Closure of Matter: The Minimum Bid Price Requirement matter, originally flagged in a deficiency letter dated July 16, 2024, is now officially closed.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements cautioning that actual results may differ due to risks and uncertainties. Specific risks mentioned include the Company's ability to maintain its listing on Nasdaq. The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the current trading price of NEUP to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the July 16, 2024, Form 8-K to understand the initial deficiency notice and the 180-day compliance window.
- Monitor future filings for any new Nasdaq deficiency notices or changes in listing status.
- Confirm the Company's re-domiciliation from Australia to Delaware, which was effective December 24, 2024, and its impact on the trading security (transition from American Depositary Shares to Common Stock).